In our model of COPD-like inflammation, IL-17C deficiency enhanced the response to PD-1 therapy without affecting the expression of PD-1 in CD8 lymphocytes and the membrane expression of PD-L1 in myeloid cells. This evidence concerns the gene CD274 and chronic obstructive pulmonary disease.